Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VTP 600

Next Previous
Search
Drug Profile

VTP 600

Alternative Names: ChAdOx1-MAGEA3-NYESO; MAGE-NY-ESO; MVA-MAGEA3; VTP-600

Latest Information Update: 17 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig Institute for Cancer Research; Vaccitech
  • Developer Barinthus Biotherapeutics; Cancer Research UK
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 02 May 2024 Barinthus Biotherapeutics in collaboration with Cancer Research UK suspends a phase I/II trial in Non-small cell lung cancer (First-line therapy, Combination therapy, Late-stage disease) in United Kingdom (Parenteral) (NCT04908111) (EudraCT2019-003015-64)
  • 18 Jan 2022 Vaccitech plans clinical trials in Cancer (Breast cancer, Malignant melanoma, Bladder cancer, Colorectal cancer)
  • 08 Dec 2021 Phase-I/II clinical trials in Non-small cell lung cancer (First-line therapy, Combination therapy) in United Kingdom (Parenteral) (NCT04908111 ; EudraCT2019-003015-64).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top